Potential side effects to GLP-1 agonists: understanding their safety and tolerability

被引:44
作者
Consoli, Agostino [1 ]
Formoso, Gloria [1 ]
机构
[1] Univ G DAnnunzio, Dept Med & Aging Sci, I-66100 Chieti, Italy
关键词
cancer risk; GLP-1 receptor agonists; incretin-based therapy; side effects; GLUCAGON-LIKE PEPTIDE-1; TYPE-2; DIABETES-MELLITUS; INCRETIN-BASED THERAPIES; METFORMIN-TREATED PATIENTS; ARTERIAL-BLOOD PRESSURE; ONCE-DAILY LIXISENATIDE; TWICE-DAILY EXENATIDE; THYROID C-CELLS; GLYCEMIC CONTROL; OPEN-LABEL;
D O I
10.1517/14740338.2015.987122
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Glucagon-like peptide 1 receptor (GLP-1Rx) agonists might elicit unwelcome side effects and concerns have recently been raised about their safety. Areas covered: Available evidence about safety, tolerability and potential adverse events relative to GLP-1Rx agonists presently used. We searched the MEDLINE database using the terms: 'GLP-1 receptor agonists', 'Incretin therapy side effects', 'exenatide', 'liraglutide', 'exenatide long-acting release', ' lixisenatide'. Articles were selected on the basis of the study design and importance, in the light of authors' clinical experience and personal judgment. The main safety concern about GLP-1Rx agonists use is the possible association with increased risk of pancreatitis and/or tumors. This concern stems mainly from limited observations in animal models not confirmed in similar studies. Furthermore, clinical studies reporting association between GLP-1Rx agonist use and pancreatitis/cancer are marred by several biases and both clinical trials and post-marketing analyses failed to demonstrate a significant association. Expert opinion: As stated by both FDA and EMA, the safety concerns emerged so far about GLP-1RX agonists should not affect present prescribing habits. Thus, although a strict data monitoring must be encouraged, they should not prevent access to the benefits of an innovative treatment, such as GLP-1Rx agonists use, to a large diabetic population still confronted with unmet needs.
引用
收藏
页码:207 / 218
页数:12
相关论文
共 111 条
[21]   Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes [J].
Davies, M. J. ;
Kela, R. ;
Khunti, K. .
DIABETES OBESITY & METABOLISM, 2011, 13 (03) :207-220
[22]   Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes [J].
DeFronzo, RA ;
Ratner, RE ;
Han, J ;
Kim, DD ;
Fineman, MS ;
Baron, AD .
DIABETES CARE, 2005, 28 (05) :1092-1100
[23]   Exenatide (Exendin-4)-induced pancreatitis - A case report [J].
Denker, PS ;
Dimarco, PE .
DIABETES CARE, 2006, 29 (02) :471-471
[24]   Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial [J].
Diamant, Michaela ;
Van Gaal, Luc ;
Stranks, Stephen ;
Northrup, Justin ;
Cao, Dachuang ;
Taylor, Kristin ;
Trautmann, Michael .
LANCET, 2010, 375 (9733) :2234-2243
[25]   Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide [J].
Dore, David D. ;
Seeger, John D. ;
Chan, K. Arnold .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) :1019-1027
[26]   Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].
Drucker, Daniel J. ;
Buse, John B. ;
Taylor, Kristin ;
Kendall, David M. ;
Trautmann, Michael ;
Zhuang, Dangliang ;
Porter, Lisa .
LANCET, 2008, 372 (9645) :1240-1250
[27]   The Safety of Incretin-Based Therapies-Review of the Scientific Evidence [J].
Drucker, Daniel J. ;
Sherman, Steven I. ;
Bergenstal, Richard M. ;
Buse, John B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (07) :2027-2031
[28]   Cardiovascular safety and diabetes drug development [J].
Drucker, Daniel J. ;
Goldfine, Allison B. .
LANCET, 2011, 377 (9770) :977-979
[29]   Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial [J].
Dungan, Kathleen M. ;
Tofe Povedano, Santiago ;
Forst, Thomas ;
Gonzalez Gonzalez, Jose G. ;
Atisso, Charles ;
Sealls, Whitney ;
Fahrbach, Jessie L. .
LANCET, 2014, 384 (9951) :1349-1357
[30]   Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment [J].
Egan, Amy G. ;
Blind, Eberhard ;
Dunder, Kristina ;
de Graeff, Pieter A. ;
Hummer, B. Timothy ;
Bourcier, Todd ;
Rosebraugh, Curtis .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (09) :794-797